|
PharmaSat was a nanosatellite developed by NASA Ames Research Center which measured the influence of microgravity upon yeast resistance to an antifungal agent. As a follow on to the GeneSat-1 mission, the Ames Small Spacecraft Division conducted the PharmaSat mission in collaboration with industry and local universities.〔http://microsatellitefreeflyer.arc.nasa.gov/docs/PharmaSat_1.pdf 〕 PharmaSat was the first nanosatellite to implement biological science guided by its Principal Investigator. The mission was designed to aid the development of medicines or techniques to enable long-term manned space travel and habitation. == Background == The PharmaSat mission builds upon technology demonstrated by GeneSat-1, which used a CubeSat to study microfluidics and optics in the space environment. It was designed to provide life-support, growth, monitoring, and analysis capabilities for microorganisms. Based, like GeneSat-1, around a three-unit CubeSat platform; PharmaSat was designed to accomplish five functions in an autonomous free-flying platform:〔(PharmaSat )〕 # Provide life support and environmental control for growth of the yeast strain in 48 independent microwells # Dose the growing yeast with antifungal agent at the appropriate point on the growth curve with three distinct, well-defined dosage levels, plus a zero-dose control # Track the population of the yeast via optical density of each microwell before, during and after antifungal administration # Determine well-by-well yeast viability at multiple, well-defined times after antifungal administration using a colorimetric reagent, Alamar Blue # Telemeter the resulting population and viability data to Earth, along with system status data. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「PharmaSat」の詳細全文を読む スポンサード リンク
|